Skip to main content
Premium Trial:

Request an Annual Quote

Assay Designs, Protedyne, Genedata, NIH Chemical Genomics Center, SRI, SciTegic

Premium

Assay Designs Raises $5M in Series A Financing

Ann Arbor, Mich.-based Assay Designs said last week that it has recently received a $5 million Series A equity investment from Ampersand Ventures.

Ampersand was the sole investor in the financing round, which was the first in Assay Designs' history.

Assay Designs, founded in 1992, develops and manufactures immunoassay kits, luminescent reagents, antibodies, and proteins for the life sciences research market.


Protedyne Opens UK Office

Protedyne said last week that it has opened an office in Essex, UK, to house the company's European sales and support groups.

The facility will be overseen by Ashley Gould, Protedyne's regional manager for Europe.

Protedyne, headquartered in Windsor, Conn., provides automation products to the life sciences market.


Genedata Provides Screening Analysis Software to NIH Chemical Genomics Center

Genedata will integrate its software for analyzing screening data with existing IT infrastructure from the NIH Chemical Genomics Center, the company said last week.

NCGC, which is developing a compound library and will perform screening assays, chose Genedata's Screener "because the software has been developed and tested successfully in a high-throughput industrial setting," Christopher Austin, the center's director, said in a statement.

Genedata Screener enables users to compare high-throughput screening data across different assays and to analyze dose-response test in high throughput.


SRI to Conduct Drug Discovery with Schering-Plough

The Southern Research Institute has entered into a collaborative research program with Schering-Plough to discover novel compounds to treat infectious disease, SRI said last week.

Building on leads generated from SRI's proprietary compound repository, scientists from both organizations will conduct lead expansion and optimization programs, SRI said. SRI will share in intellectual property and receive milestone payments resulting from the work.

Further financial details were not disclosed.


SciTegic Acquisition Helps Boost Accelrys Q4 Revenues 70 Percent

Accelrys reported 70-percent revenue growth amid narrowed losses for the fourth quarter of its 2005 fiscal year last week.

Accelrys said that sales from SciTegic, which it acquired in September 2004, along with "strong growth" in sales of its core products, led to orders of $19.1 million for the quarter ended March 31, 2005, an 88-percent increase over $10.1 million in orders reported in the same period of 2004.

Reported revenue, which includes the impact of deferred revenue from the company's subscription accounting model, increased 70 percent to $18.9 million, from $11.1 million in the year-ago period.

Accelrys did not break out quarterly orders or revenue numbers for SciTegic.

In January, CBA News reported that Accelrys believes its acquisition of SciTegic provides it with several products that may be useful for data management in high-content image-based screening (see CBA News, 1/25/2005).

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.